Literature DB >> 19877250

Extended bile duct resection and [corrected] liver and transplantation in patients with hilar cholangiocarcinoma: long-term results.

Daniel Seehofer1, Armin Thelen, Ulf P Neumann, Winfried Veltzke-Schlieker, Timm Denecke, Carsten Kamphues, Johann Pratschke, Sven Jonas, Peter Neuhaus.   

Abstract

For patients with irresectable hilar cholangiocarcinoma, liver transplantation (LT) is currently being reassessed because of promising data for neoadjuvant radiochemotherapy. For increased radicality, hepatectomy in combination with pancreatic head resection [extended bile duct resection (EBDR)] was performed for irresectable hilar cholangiocarcinoma during our initial experience. EBDR and LT was performed in 16 patients between 1992 and 1998. No neoadjuvant or adjuvant treatment was performed. The Union Internationale Contre le Cancer stages were I (n = 6), IIA (5), IIB (3), and IV (2). To evaluate the suspected increase in surgical radicality, a matched pair analysis was performed with 8 patients undergoing LT for hilar cholangiocarcinoma without partial pancreatoduodenectomy. The 1-, 5-, and 10-year patient survival rates after EBDR were 63%, 38%, and 38%, respectively. Twelve patients died: 2 died because of postoperative complications, 8 died because of tumor recurrence, and 2 died while recurrence-free more than 10 years after transplantation. Among the 6 stage I patients, only 1 developed tumor recurrence, but 2 died because of postoperative complications. The following factors showed a trend toward inferior survival: distant metastases, positive lymph nodes, high carbohydrate antigen 19-9 levels, and preoperative percutaneous transhepatic cholangiodrainage. When all lymph node-negative patients were considered after the exclusion of perioperative deaths, 10-year survival was 56%. In conclusion, the overall long-term survival was relatively low in our inhomogeneous cohort but favorable in patients without metastases. However, because of the increased perioperative mortality, EBDR is not recommended as a standard procedure for hilar cholangiocarcinoma instead of LT alone. To further improve the results, other approaches such as (neo)adjuvant therapy have to be increasingly investigated.

Entities:  

Mesh:

Year:  2009        PMID: 19877250     DOI: 10.1002/lt.21887

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

Review 1.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Authors:  Evan S Glazer; Ping Liu; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley
Journal:  J Gastrointest Surg       Date:  2012-07-10       Impact factor: 3.452

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 4.  Liver transplantation for hilar cholangiocarcinoma.

Authors:  Ricardo Robles; Francisco Sánchez-Bueno; Pablo Ramírez; Roberto Brusadin; Pascual Parrilla
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 5.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

6.  Pancreaticoduodenectomy after liver transplantation in patients with primary sclerosing cholangitis complicated by distal pancreatobiliary malignancy.

Authors:  Robert P Sutcliffe; Wayne Lam; Adrian O'Sullivan; Andreas Prachalias; Mohamed Rela; Nigel Heaton
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 7.  Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.

Authors:  Enrico Gringeri; Martina Gambato; Gonzalo Sapisochin; Tommy Ivanics; Erica Nicola Lynch; Claudia Mescoli; Patrizia Burra; Umberto Cillo; Francesco Paolo Russo
Journal:  J Clin Med       Date:  2020-05-05       Impact factor: 4.241

Review 8.  Surgery for cholangiocarcinoma.

Authors:  Umberto Cillo; Constantino Fondevila; Matteo Donadon; Enrico Gringeri; Federico Mocchegiani; Hans J Schlitt; Jan N M Ijzermans; Marco Vivarelli; Krzysztof Zieniewicz; Steven W M Olde Damink; Bas Groot Koerkamp
Journal:  Liver Int       Date:  2019-05       Impact factor: 5.828

9.  Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study.

Authors:  Andrej Wagner; Marcus Wiedmann; Andrea Tannapfel; Christian Mayr; Tobias Kiesslich; Gernot W Wolkersdörfer; Frieder Berr; Johann Hauss; Helmut Witzigmann
Journal:  Int J Mol Sci       Date:  2015-11-06       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.